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Background: MicroRNAs are non-coding small RNAs that regulate expression of target genes by binding
to 30 untranslated regions. In this study, we used bronchial epithelial cells to investigate in vitro the role
of the microRNA miR-155 in the expression of chemokines associated with airway inﬂammation. miR-
155 has previously been reported to regulate allergic inﬂammation.
Methods: BEAS-2B bronchial epithelial cells were cultured and transfected with mimic or inhibitor oli-
gonucleotides to overexpress or downregulate miR-155, as conﬁrmed by real-time PCR. Cells were then
stimulated with tumor necrosis factor-alpha, interleukin-13 (IL-13), and a double stranded RNA that
binds Toll-like receptor 3. Expression and secretion of the chemokines CCL5, CCL11, CCL26, CXCL8, and
CXCL10 were then quantiﬁed by real-time PCR and ELISA, respectively. Phosphorylation of signal
transducer and activator of transcription 6 (STAT6), a target of the IL-13 receptor, was analyzed by ELISA.
Results: miR-155 overexpression signiﬁcantly suppressed IL-13-induced secretion of CCL11 and CCL26.
These effects were speciﬁc, and were not observed for other chemokines, nor in cells with down-
regulated miR-155. miR-155 overexpression also suppressed CCL11 and CCL26 mRNA, but did not affect
expression of the IL-13 receptor or phosphorylation of STAT6.
Conclusions: miR-155 speciﬁcally inhibits IL-13-induced expression of eosinophilic chemokines CCL11
and CCL26 in bronchial epithelial cells, even though the 3'-untranslated region of these genes do not
contain a consensus binding site for miR-155.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).y Internal Medicine, Showa
u, Yokohama-shi, Kanagawa
Matsukura).
ety of Allergology.
rgology. Production and hosting by ElseIntroduction
microRNAs (miRNAs) are small non-coding RNAs of 18e25 nu-
cleotides that regulate gene expression via a “seed” region, which
speciﬁcally binds to the 3'-untranslated region of the target mRNA
to suppress translation or induce degradation. Accumulating evi-
dence suggests that miRNAs regulate an array of biological pro-
cesses, including inﬂammation and allergic disease.1vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
S. Matsukura et al. / Allergology International 65 (2016) S17eS23S18A growing body of research suggests that the microRNA miR-155
might play an important role in the pathogenesis of asthma,2 a
common airway disease characterized by damage, chronic inﬂam-
mation, and hyperresponsiveness in the bronchial epithelia. For
instance, Rodriguez et al.3 reported that a defect in miR-155 in a
mouse model causes airway inﬂammation and other pathological
features that resemble asthma. Decreased expression ofmiR-155 has
also been observed in the airway of asthmatic patients.4e6 In addi-
tion, Martinez-Nunenz et al.7 demonstrated that miR-155 directly
targets interleukin-13 receptor alpha 1 and suppresses its expression
in human macrophages. Finally, miR-155 inhibits the replication of
human rhino virus, which frequently exacerbates asthma.8 Thus,
investigation of the clinical relevance of miRNAs to allergic and/or
pulmonary diseases would advance diagnosis and therapy. Indeed,
therapeutic approaches based on miRNA seem promising in light of
the ability of speciﬁc miRNAs to modulate multiple molecular pro-
cesses associated with disease pathogenesis.9,10
Chemokines from bronchial epithelial cells have also been re-
ported to contribute to chronic airway inﬂammation by recruiting
inﬂammatory cells. In particular, Larose et al.11 recently reported
that CC chemokine ligand 26 (CCL26) is abundantly expressed in
the epithelium of patients with severe asthma. CCL26 and CCL11
are believed to be induced by key Th2 cytokines like interleukin-13
(IL-13) to elicit eosinophilic inﬂammation via CC chemokine re-
ceptor 3.12,13 In addition, we have demonstrated that the cytokines
tumor necrosis factor-alpha (TNF-a) and IL-13, as well as a double-
stranded RNA (dsRNA) that binds Toll-like receptor 3, differentially
regulate expression of the inﬂammatory chemokines CCL11/
Eotaxin, CCL26/Eotaxin-3, CCL5/RANTES, CXCL8/IL-8, and CXCL10/
IP-10 in bronchial epithelial cells.12,14e16
In this study, we characterized for the ﬁrst time the role of miR-
155 in the expression of inﬂammatory chemokines in bronchial
epithelial cells, as well as the underlying molecular mechanisms.
Methods
Cell culture and reagents
The BEAS-2B human airway epithelial cell line was purchased
from the American Type Culture Collection (Manassas, VA, USA).
This cell line was derived from non-tumor bronchial epithelial cells
transformed with SV40.17 Cells were grown at 37 C in a humidiﬁed
atmospherewith 5% CO2, in Dulbecco's modiﬁed Eaglemedium/F12
medium supplemented with 10% fetal bovine serum, 100 U/mL
penicillin, and 100 ng/mL streptomycin (Invitrogen, Tokyo, Japan).
Recombinant human cytokines TNF-a and IL-13 were purchased
from R & D Systems (Tokyo, Japan). An agonist of Toll-like receptor
3 (TLR3), synthetic dsRNA poly IC was obtained from Sigma-
eAldrich (Tokyo, Japan). Culture supernatant, RNA, and cell lysates
were collected, and stored at 80 C until experiments.
Chemokine secretion
The concentration of CCL11, CCL26, CCL5, CXCL8, and CXCL10 in
the cell culture supernatant was measured using enzyme-linked
immunosorbent assay (ELISA) kits (R&D Systems) according to
the manufacturer's protocol, and as described previously.14,16 The
ELISA plate reader Glomax-Multi Detection System (Promega,
Tokyo, Japan) was used to measure absorbance.
mRNA expression
Total RNA was extracted from cell cultures, and transcribed with
High-Capacity cDNA Archive Kit (Applied Biosystems, Tokyo, Japan).
Abundance of CCL11, CCL26, CCL5, CXCL8, CXCL10, and IL-13 receptoralpha 1 mRNA was measured by real-time polymerase chain reac-
tion (PCR) using TaqMan probes and Real-Time PCR System 7500
(Applied Biosystems, Tokyo, Japan), as described previously.14,16
Transfection of miR-155 inhibitor or mimic
miR-155 mimic (hsa-miR-155, mirVana™ miRNA mimic), miR-
155 inhibitor (hsa-miR-155, mirVana™ miRNA inhibitor), and
negative control miRNA were purchased from Ambion (Tokyo,
Japan). The inhibitor is a pre-designed antisense oligonucleotide
that downregulates miR-155. Themimic contains same sequence of
endogenous miR-155 and can increase the expression level of miR-
155. It is known to show same function as mature endogenousmiR-
155. Negative control miRNA is a non-speciﬁc oligonucleotide with
a random sequence and without measurable effects. BEAS-2B cells
were seeded in 6-well plates, cultured to 50% conﬂuence, trans-
fected with 25 nM miRNAs in 5 mL Lipofectamine 2000 (Promega,
Tokyo, Japan), and grown for 24 h in Dulbecco's modiﬁed Eagle
medium/F12 medium with 10% fetal bovine serum and without
antibiotics. Media were then replaced with fresh media supple-
mented with 100 U/mL penicillin, and 100 ng/mL streptomycin.
After another 24 h, cells were stimulated with cytokines or dsRNA.
Finally, cells and supernatant were harvested 24 h after stimulation.
miR-155 expression
Total miRNA was extracted from cells using mirVana™ miRNA
Isolation Kit (Ambion, Tokyo, Japan), following the manufacturer's
protocol. Puriﬁed RNA (5 ng) was transcribed with TaqMan
microRNA reverse transcription kit (Applied Biosystems) as
described in the manufacturer's protocol, and ampliﬁed with a
primer set for miR-155, using HY3 as endogenous control. Pre-
designed TaqMan probes for miR-155 and HY3 were purchased
from Applied Biosystems. The probes are labeled with a FAM
ﬂuorescent reporter dye at the 50 end, and a TAMRA quencher dye
at the 30 end. Each reaction consisted of 2 Universal Master Mix II
(Applied Biosystems), primers, labeled probes, and 6.5 ng cDNA in a
total volume of 40 mL. Reactions were initially denatured at 95 C
for 10 min, and then ampliﬁed over 40 cycles at 95 C for 15 s and
60 C for 1 min using a Real-Time PCR system 7500 (Applied Bio-
systems). Fluorescence was measured during the elongation step.
Data are reported as fold induction relative to untransfected cells.
STAT6 phosphorylation
STAT6 phosphorylation was quantiﬁed using PathScan phospho-
STAT6 sandwich ELISA kit (Cell Signaling Technology Japan, Tokyo,
Japan). Brieﬂy, cells were incubated with or without 10 ng/mL IL-13
for 10 or 20 min, harvested with a scraper, and lysed in lysis buffer.
Lysates were added to 96-well microtiter plates coated with anti-
bodies speciﬁc for STAT6 phosphorylated at Tyr641. After incubation
at 37 C for 2 h, wells were washed four times with wash buffer,
incubated at 37 C for 1 h with an antibody against phosphorylated
STAT6, and washed another four times with wash buffer. Wells were
then probed at 37 C for 30 min with a secondary antibody conju-
gated to horseradish peroxidase, washed four times with wash
buffer, and reacted at 37 C for 30 min with tetramethylbenzidine.
The reaction was terminated with stop solution, and absorbance at
450 nm was measured using the ELISA plate reader Glomax-Multi
Detection System (Promega). Data are reported as optical density.
Stability of CCL11 and CCL26 mRNA
To determine the effect of miR-155 overexpression on the sta-
bility of CCL11 and CCL26 mRNA, we treated BEAS-2B cells with
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S. Matsukura et al. / Allergology International 65 (2016) S17eS23 S1910 ng/mL IL-13 for 24 h after transfection with negative control
(miR-control) or miR-155 mimic. Cells were then either harvested
or treated with transcription inhibitor actinomycin D (3 mg/mL) for
indicated time, and then subjected to real-time PCR to determine
the decay of the chemokines' mRNA.
Statistical analysis
Data are reported as mean ± standard error of the mean (SEM).
Data were analyzed in Stat-View 5.0 (Abacus Concepts, Inc., Ber-
keley, CA, USA) by analysis of variance with Fisher's protected least
signiﬁcant difference test.
Results
Downregulation or overexpression of miR-155 in bronchial
epithelial cells
miR-155 expression was signiﬁcantly down regulated in BEAS-
2B bronchial epithelial cells transfected with miR-155 inhibitor
than in cells transfected with negative control (miR-control)miR-control miR-155
inhibitor
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Fig. 1. Expression of miR-155 in BEAS-2B bronchial epithelial cells transfected with
25 nM miR-155 inhibitor (A) and mimic (B), as measured by real-time PCR. A non-
speciﬁc miRNA was used as negative control (miR-control). Data are mean ± SEM of
three independent experiments. *p < 0.05 vs. cells transfected with miR-control. NS
means not-signiﬁcance.(*p < 0.05, Fig. 1A), but was signiﬁcantly upregulated in cells
transfected with miR-155 mimic than in cells transfected with
negative control (miR-control) (*p < 0.05, Fig.1B). Transfectionwith
miR-control did not change the expression level of miR-155 (NS
means not-signiﬁcance).CCL11 and CCL26 secretion in cells stimulated with IL-13
As previously reported,12 CCL11 secretion increased within 24 h
(*p < 0.05) in untransfected cells treated with TNF-a and IL-13, but
not in untransfected cells treated with dsRNA (Fig. 2A). Similar
results were obtained in cells transfected with miR-negative
control or miR-155 inhibitor. However, miR-155 overexpression
via miR-155 mimic signiﬁcantly blocked the increase in CCL11
secretion due to IL-13, with **p < 0.05 when compared to the cells
transfected with miR-control and stimulated with IL-13. miR-155(B)
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Fig. 2. Secretion of the eosinophilic chemokines CCL11/Eotaxin (A) and CCL26/Eotaxin-
3 (B) by BEAS-2B bronchial epithelial cells. Cells transfected with or without miR-155
mimic, inhibitor, or negative control (miR-control) were stimulated for 24 h with
10 ng/mL IL-13, 10 ng/mL TNF-a, or 50 mg/mL dsRNA poly IC. Cell culture supernatants
were analyzed by ELISA. Data are mean ± SEM of three independent experiments.
*p < 0.05 vs. unstimulated cells (cont) with same situation; **p < 0.05 vs. cells
transfected with miR-cont and exposed to the same stimulant.
S. Matsukura et al. / Allergology International 65 (2016) S17eS23S20overexpression seemed to block CCL11 production in cells treated
with TNF-a, but not to a statistically signiﬁcant extent. In
untransfected cells, IL-13 and dsRNA stimulated secretion of
CCL26 within 24 h (*p < 0.05, Fig. 2B). However, TNF-a stimulated
CCL26 secretion only slightly, and not to a statistically signiﬁcant
extent. The same effects were observed in cells transfected with
miR-155 inhibitor and negative control. However, production of
CCL26 due to IL-13 was signiﬁcantly blocked in cells over-
expressing miR-155 via miR-155 mimic, with **p < 0.05 relative to
cells transfected with miR-control and stimulated with IL-13.
Notably, production of CCL26 due to dsRNA was independent of
miR-155 overexpression.(A)
(B)
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Fig. 3. Production of the chemokines CCL5/RANTES (A), CXCL8/IL-8 (B), and CXCL10/
IP-10 (C) by BEAS-2B bronchial epithelial cells transfected with or without miR-155
mimic, inhibitor, or negative control (miR-control), and stimulated for 24 h with
10 ng/mL IL-13, 10 ng/mL TNF-a, or 50 mg/mL dsRNA poly IC. Chemokines secreted
into the cell culture supernatants were measured by ELISA. Data are mean ± SEM of
three independent experiments. *p < 0.05 vs. unstimulated cells (cont) with same
situation; **p < 0.05 vs. cells transfected with miR-control and exposed to the same
stimulant.Effect of miR-155 on secretion of CCL5, CXCL8, and CXC10
In untransfected cells, TNF-a stimulated production of CXCL8
(Fig. 3B), while dsRNA increased production of CCL5 (Fig. 3A),
CXCL8 (Fig. 3B), and CXCL10 (Fig. 3C) 24 h after exposure
(*p < 0.05), as previously reported.14 However, IL-13 did not in-
crease secretion. Notably, miR-155 overexpression via miR-155
mimic did not inhibit secretion, indicating that the miRNA spe-
ciﬁcally blocks CCL11 and CCL26 production due to IL-13. On the
other hand, negative control (miR-control), mimic, and inhibitor
miRNAs seemed to relatively enhance chemokine production in
response to dsRNA.
CCL11 and CCL26 mRNA
We then investigated the mechanisms underlying the ability of
miR-155 to block CCL11 and CCL26 production due to IL-13. In the
cells transfected with negative control miRNA, the abundance of
CCL11 (Fig. 4A) and CCL26 mRNA (Fig. 4B) increased 24 h after
stimulation with IL-13 (*p < 0.05). These effects were blocked by(A)
(B)
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Fig. 4. Abundance of CCL11/Eotaxin (A) and CCL26/Eotaxin-3 (B) mRNA in BEAS-2B
bronchial epithelial cells. Cells were transfected with miR-155 mimic, inhibitor, or
negative control (miR-control), stimulated for 24 h with 10 ng/mL IL-13, 10 ng/mL TNF-
a, or 50 mg/mL dsRNA poly IC, and analyzed by real-time PCR. Data are mean ± SEM of
three independent experiments. *p < 0.05 vs. unstimulated cells (cont); **p < 0.05 vs.
cells transfected with negative control and exposed to the same stimulant.
S. Matsukura et al. / Allergology International 65 (2016) S17eS23 S21overexpression of miR-155 cells via miR-155 mimic, with **p < 0.05
relative to IL-13-stimulated cells transfected with negative control
miRNA (miR-control), even though the 30UTR in these chemokines
do not contain the consensus binding site for miR-155.
Effects of miR-155 overexpression on IL-13 signaling
We then hypothesized that miR-155 might regulate IL-13
signaling upstream of CCL11 or CCL26 mRNA synthesis. We found
that BEAS-2B bronchial epithelial cells constitutively expressed IL-
13 receptor alpha 1, and expressionwas not suppressed bymiR-155
overexpression via miR-155 mimic (Fig. 5A), in contrast to pub-
lished data in macrophages.7 We also analyzed the effect of miR-
155 overexpression on IL-13 signaling downstream of the IL-13
receptor. As expected, IL-13 induced phosphorylation of STAT6
(Fig. 5B), a key transcription factor for that regulates CCL11 and
CCL26 expression.12,18,19We found that miR-155 overexpression did
not interfere with STAT6 phosphorylation in cells exposed to IL-13.
Effect of miR-155 overexpression on the mRNA stability
Results of real-time PCR for CCL11 (Fig. 6A) and CCL26 (Fig. 6B)
showed stability of mRNA for these chemokines decreased after
adding actinomycin D at 4 h (*p < 0.05 vs. cells at time 0 h). We(A)
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Fig. 5. Expression IL-13 receptor alpha 1, as measured by real-time PCR, in BEAS-2B
bronchial epithelial cells overexpressing miR-155 via miR-155 mimic (A). STAT6
phosphorylation, as measured by ELISA, in BEAS-2B cells transfected with indicated
miRNAs, and stimulated with 10 ng/mL IL-13 for 10 or 20 min (B). Data are
mean ± SEM of three independent experiments. *p < 0.05 vs. unstimulated cells (time
0 h) with same situation.hypothesized that overexpression of miR-155 might accelerate the
decay of chemokines' mRNA, if miR-155 directly binds and in-
terferes with mRNA for CCL11 or CCL26. However, level of decay of
chemokines' mRNA were not different between cells transfected
with negative control (miR-control) and the cells transfected with
miR-155 mimic. These data indicate that the effect of miR-155
overexpression may not be derived from direct interference with
chemokines' mRNA.
Discussion
In this study, we demonstrated that in BEAS-2B bronchial
epithelial cells, miR-155 blocks secretion of CCL11 and CCL26 due to
the Th2 cytokine IL-13. However, miR-155 did not block dsRNA or
TNFa-induced secretion of other chemokines such as CCL5, CXCL8,
and CXCL10. Accordingly, miR-155 downregulated CCL11 and
CCL26 mRNA expression, as measured by real-time PCR. Never-
theless, downregulation of miR-155 did not stimulate expression of
CCL11 and CCL26, in contrast to expectation. Finally, miR-155
overexpression did not suppress expression of the IL-13 receptor
or alter the phosphorylation of its downstream target STAT6.
The effects of miR-155 overexpression did not seem to be
experimental artifacts, as non-speciﬁc control oligonucleotides did
not block IL-13-induced expression of CCL11 and CCL26. In addition,
the effects of miR-155 also seemed to be dose-dependent over
5e50 nM in preliminary experiments (data not shown). Further, we(A)
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Fig. 6. Effect of overexpression of miR-155 on the decay of mRNA for CCL11/Eotaxin (A)
and CCL26/Eotaxin-3 (B) in BEAS-2B cells. Cells were transfected with negative control
(miR-control) (open circle) or miR-155 mimic (closed triangle) and treated with the
transcription inhibitor actinomycin D (3 mg/mL) for the indicated time after pretreat-
ment with 10 ng/mL IL-13 for 24 h. Quantiﬁcation of mRNA was performed with real-
time PCR and the data were expressed as fold induction of cells time 0 h (not treated
with actinomycin D). Data are representatives of three independent experiments.
*p < 0.05 vs. cells not treated with actinomycin D (time 0 h) with same situation.
S. Matsukura et al. / Allergology International 65 (2016) S17eS23S22also conﬁrmed that several miRNAs, including miR-21 and miR-
146, did not interfere with chemokine expression (data not
shown). Finally, we veriﬁed that miR-155 overexpression did not
impact cell viability (data not shown).
We need further studies to clarify the reason why miR-155 in-
hibitor failed to show any effect on the chemokines' expression,
however we hypothesize that the degree of inhibitory effect and
other miRNAs may be involved. Martinez-Nunez RT et al. have been
reported that downregulation of miR-155 did not alter the
expression of inﬂammatory cytokines in epithelial cells, but
downregulation of multiple miRNAs, such as miR-155, miR18a,
miR-27a and miR-128, resulted in the upregulation of IL-6 and IL-
8.5 These data suggest that somemiRNA compensate othermiRNA's
function andmultiple miRNAs co-operatively regulate targetmRNA
expression. In our study, we hypothesize that function of down-
regulation of miR-155 may be compensated by other miRNA. The
degree of downregulation of miR-155 expression level seemed to
be lower than that of miR-155 overexpression. Remarkable level of
overexpressed miR-155 may be necessary for getting its function to
downregulate the expression of CCL11 and CCL26. Level of miR-155
constitutively expressed in BEAS-2B cells might not be enough to
suppress the expression of CCL11 or CCL26.
We used TargetScan for bioinformatic analysis to analyze
whether miR-155 can bind 30UTR of CCL11 or CCL26. It is the web
server and predicts the presence of 8 or 7mer sites in the target
mRNA that match seed region in each miRNA. The seed region is
essential for the binding of miRNA to the target mRNA and should
be complementary with the sequence of target 30UTR.20 It is mostly
situated at positions 2e8 of the miRNA 5’-end. We analyzed the
30UTR of CCL11 and CCL26 mRNA and could not ﬁnd conserved
binding site for miR-155 in these chemokines. Accordingly, our data
suggested that miR-155 overexpression did not interfere with the
stability of CCL11 and CCL26 mRNA. Therefore, we hypothesized
that the inhibitory effects of miR-155 on chemokine production
may be indirect, we need further studies to conﬁrm these hy-
pothesis using reporter plasmids containing 30UTR of these che-
mokines however.
Thus, we tested whether miR-155 might suppress expression of
IL-13 receptor alpha 1 in BEAS-2B cells. However, we found that
miR-155 does not suppress IL-13 receptor alpha 1 in these cells, as it
does in macrophages.7 This discrepancy may be due to differences
between cell types. It has been documented that role of miRNAs is
sometimes different between cell types.21 For example, some in-
vestigators have reported that miR-155 targets transcription factors
Smad 2 and Smad 5, and directly suppress these factors' expression
inmacrophage.22,23 On the hand, Yao R. et al. has reported thatmiR-
155 could not directly inhibit the expression of Smad 2 or Smad 5.24
These mechanisms have not been clariﬁed in details, but the in-
vestigators discussed that many kinds of miRNAs regulate the
target genes and miRNA tends to inhibit different transcripts in a
cell-speciﬁc manner. In addition to the difference of cell type,
different protocol and system of experiments may inﬂuence the
results.21
We also analyzed STAT6 phosphorylation, a key transcription
factor that stimulates transcription of CCL11 and CCL26 in response
to IL-13. We found that miR-155 overexpression also did not affect
STAT6 phosphorylation in BEAS-2B cells.
Thus, further research is necessary to elucidate the mechanisms
underlying the ability miR-155 to block the effects of IL-13 on
expression of CCL11 and CCL26. We now hypothesize that the
transcription factor PU.1 may be involved. PU.1 stimulates tran-
scription of target genes via STAT6, and expression of PU.1 itself is
repressed via a binding site for miR-155.25,26 Consequently, miR-
155 overexpression may block the effects of IL-13 if PU.1 is
involved in the IL-13 pathway of CCL11 or CCL26 induction. In ourresults, miR-155 overexpression did not inhibit the expression of
CCL11 or CCL26 stimulated with TNF-a. We hypothesize that these
mechanismsmay be also explained by the role of PU.1, because PU.1
may not interact with NF-kB, a responsible transcription factor for
TNF-a signaling.
We showed the differential regulation of chemokine expression
by cytokines or dsRNA. We have previously compared the effects of
stimulationwith dsRNA on the expression of chemokines in airway
epithelial cells.14 The effects were grater on the expression of CCL5
and CXCL10 than CXCL8 or CCL26. It did not stimulate CCL11
expression. We hypothesized that structure of chemokine's pro-
moter region may be responsible for the activation of chemokine
expression through TLR3 signaling. CCL5 and CXCL10 contain the
response element for two important transcription factors, nuclear
factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF-3),
on the other hand, CXCL8 or CCL26 contains the response element
for only NF-kB. Cooperative activation with both NF-kB and IRF-3
may be necessary for signiﬁcant stimulation of the chemokine
expression. IL-13 increased the expression of CCL11 and CCL26,
while it did not stimulate other chemokines. Consensus sequence
for STAT6 binding is TTCN3/4GAA.18 These putative sequence for
STAT6 exist in the promoter region of these chemokines, however
there are no report to show binding of STAT6 to theses chemokines'
promoter in our knowledge.27e29 These chemokines are known to
be less responsive to Th2 cytokine. Some investigators have also
reported that CXCL10 expression was independent to STAT6 using
STAT6-deﬁcient mice.30 In addition, we could not ﬁnd any
consensus binding site of miR-155 in the 30UTR region of CCL5,
CXCL8, or CXCL10 using TargetScan. Taken together, IL-13-STAT6
signaling may not be involved in the stimulation of CCL5, CXCL8 or
CXCL10 expression. If miR-155-PU.1 interaction would be speciﬁc
for STAT6 function, miR-155 may not interfere with the expression
of CCL5, CXCL8 or CXCL10.
Newly discovered cytokines derived from bronchial epithelial
cells, such as thymic stromal lymphopoietin, IL-33 and IL-25, would
be very important in the initiation of Th2-type response in
asthma.31 These cytokines may contribute to stimulate CCL11 or
CCL26 through production of Th2 cytokine and subsequent pro-
longed eosinophilic inﬂammation in airway. To elucidate the role of
miR-155 in the pathogenesis of asthma, we need further studies to
examine whether miR-155 inﬂuence some effects on the produc-
tion of these new cytokines.
In any case, the results indicate that miR-155 may negatively
regulate inﬂammatory factors related to Th2-type immunity, in
accordance with previous reports. Indeed, decreased expression of
miR-155 in the epitheliummay indicate a lack of anti-inﬂammatory
activity in the airway, and contribute to the development of
asthma.4e6
In summary, our results demonstrate that overexpression of
miR-155 in BEAS-2B bronchial epithelial cells signiﬁcantly sup-
presses IL-13-induced production of CCL11 and CCL26, which are
chemoattractants for eosinophils. While further studies in primary
epithelial cells are required to elucidate the underlying mechanism
in detail, our data provide new opportunities to exploit miR-155 in
asthma therapy.Acknowledgments
The authors acknowledge grants awarded by Showa University
Medical Foundation and MSD K.K. The authors also thank Drs.
Kazuaki Inoue and Keiko Takeuchi for kind assistance.Conﬂict of interest
The authors have no conﬂict of interest to declare.
S. Matsukura et al. / Allergology International 65 (2016) S17eS23 S23Authors' contributions
All authors managed the study. SM and FK designed the study and are respon-
sible for grants. SM performedmost experiments, and wrote the manuscript. YO, AS,
DI, YK, TF, HTak, YY, and HTat collected data. GI, YT, AW, EK, MH, FY, KK, and HS
analyzed and interpreted data.References
1. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA
expression proﬁles classify human cancers. Nature 2005;435:834e8.
2. Lu TX, Rothenberg ME. Diagnostic, functional, and therapeutic roles of micro-
RNA in allergic diseases. J Allergy Clin Immunol 2013;132:3e13. quiz 14.
3. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al.
Requirement of bic/microRNA-155 for normal immune function. Science
2007;316:608e11.
4. Pinkerton M, Chinchilli V, Banta E, Craig T, August A, Bascom R, et al. Differ-
ential expression of microRNAs in exhaled breath condensates of patients with
asthma, patients with chronic obstructive pulmonary disease, and healthy
adults. J Allergy Clin Immunol 2013;132:217e9.
5. Martinez-Nunez RT, Bondanese VP, Louaﬁ F, Francisco-Garcia AS, Rupani H,
Bedke N, et al. A microRNA network dysregulated in asthma controls IL-6
production in bronchial epithelial cells. PLoS One 2014;9:e111659.
6. Suojalehto H, Lindstrom I, Majuri ML, Mitts C, Karjalainen J, Wolff H, et al.
Altered microRNA expression of nasal mucosa in long-term asthma and allergic
rhinitis. Int Arch Allergy Immunol 2014;163:168e78.
7. Martinez-Nunez RT, Louaﬁ F, Sanchez-Elsner T. The interleukin 13 (IL-13)
pathway in human macrophages is modulated by microRNA-155 via direct
targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem
2011;286:1786e94.
8. Bondanese VP, Francisco-Garcia A, Bedke N, Davies DE, Sanchez-Elsner T.
Identiﬁcation of host miRNAs that may limit human rhinovirus replication.
World J Biol Chem 2014;5:437e56.
9. Stahlhut C, Slack FJ. Combinatorial action of MicroRNAs let-7 and miR-34
effectively synergizes with erlotinib to suppress non-small cell lung Cancer
cell proliferation. Cell Cycle 2015;14:2171e80.
10. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K,
et al. Treatment of HCV infection by targeting microRNA. N Engl J Med
2013;368:1685e94.
11. Larose MC, Chakir J, Archambault AS, Joubert P, Provost V, Laviolette M, et al.
Correlation between CCL26 production by human bronchial epithelial cells and
airway eosinophils: involvement in patients with severe eosinophilic asthma.
J Allergy Clin Immunol 2015;136:904e13.
12. Matsukura S, Stellato C, Georas SN, Casolaro V, Plitt JR, Miura K, et al. Inter-
leukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-
dependent mechanism. Am J Respir Cell Mol Biol 2001;24:755e61.
13. Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. World Al-
lergy Organ J 2011;4:54e64.
14. Matsukura S, Kokubu F, Kurokawa M, Kawaguchi M, Ieki K, Kuga H, et al.
Synthetic double-stranded RNA induces multiple genes related to inﬂamma-
tion through toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in
airway epithelial cells. Clin Exp Allergy 2006;36:1049e62.15. Ieki K, Matsukura S, Kokubu F, Kimura T, Kuga H, Kawaguchi M, et al. Double-
stranded RNA activates RANTES gene transcription through co-operation of
nuclear factor-kappaB and interferon regulatory factors in human airway
epithelial cells. Clin Exp Allergy 2004;34:745e52.
16. Matsukura S, Kurokawa M, Homma T, Watanabe S, Suzuki S, Ieki K, et al. Basic
research on virus-induced asthma exacerbation: inhibition of inﬂammatory
chemokine expression by ﬂuticasone propionate. Int Arch Allergy Immunol
2013;161(Suppl 2):84e92.
17. Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, Su RT, et al. Trans-
formation of human bronchial epithelial cells by infection with SV40 or
adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate
coprecipitation with a plasmid containing SV40 early region genes. Cancer Res
1988;48:1904e9.
18. Matsukura S, Stellato C, Plitt JR, Bickel C, Miura K, Georas SN, et al. Activation of
eotaxin gene transcription by NF-kappa B and STAT6 in human airway
epithelial cells. J Immunol 1999;163:6876e83.
19. Hoeck J, Woisetschlager M. Activation of eotaxin-3/CCLl26 gene expression in
human dermal ﬁbroblasts is mediated by STAT6. J Immunol 2001;167:
3216e22.
20. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of
mammalian microRNA targets. Cell 2003;115:787e98.
21. Persson JL. miR-155 meets the JAK/STAT pathway. Cell Cycle 2013;12:2170.
22. Louaﬁ F, Martinez-Nunez RT, Sanchez-Elsner T. MicroRNA-155 targets SMAD2
and modulates the response of macrophages to transforming growth factor-
{beta}. J Biol Chem 2010;285:41328e36.
23. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links
microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad
Sci U S A 2010;107:3111e6.
24. Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X, et al. MicroRNA-155 modulates Treg
and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS
One 2012;7:e46082.
25. Stutz AM, Woisetschlager M. Functional synergism of STAT6 with either NF-
kappa B or PU.1 to mediate IL-4-induced activation of IgE germline gene
transcription. J Immunol 1999;163:4383e91.
26. Lu D, Nakagawa R, Lazzaro S, Staudacher P, Abreu-Goodger C, Henley T, et al.
The miR-155-PU.1 axis acts on Pax5 to enable efﬁcient terminal B cell differ-
entiation. J Exp Med 2014;211:2183e98.
27. Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM. Genomic organi-
zation and transcriptional regulation of the RANTES chemokine gene.
J Immunol 1993;151:2601e12.
28. Ohmori Y, Hamilton TA. Cooperative interaction between interferon (IFN)
stimulus response element and kappa B sequence motifs controls IFN gamma-
and lipopolysaccharide-stimulated transcription from the murine IP-10 pro-
moter. J Biol Chem 1993;268:6677e88.
29. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human
monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989;143:
1366e71.
30. Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME.
Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6,
and IFN-gamma. J Immunol 2004;173:7565e74.
31. Divekar R, Kita H. Recent advances in epithelium-derived cytokines (IL-33, IL-
25, and thymic stromal lymphopoietin) and allergic inﬂammation. Curr Opin
Allergy Clin Immunol 2015;15:98e103.
